Posted 20th April 2020 by Liv Sewell
We recently caught up with Dr Olulanu Aina, Scientific Director and Veterinary and Toxicological Pathologist at Janssen, about digital pathology applications in drug discovery...
Posted 23rd October 2019 by Joshua Sewell
Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.
Posted 2nd October 2019 by Joshua Sewell
We’re looking back at the highlights from the Digital Pathology and AI meeting in 2018 as we anticipate this year’s Digital Pathology and AI Congress in December. This second post in our mini-series reviews Marylin Bui’s keynote presentation where she explained how the combination of Digital Pathology and Artificial Intelligence (AI) holds huge potential for patient care.
Posted 3rd June 2019 by Joshua Sewell
There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.
Posted 31st May 2019 by Joshua Sewell
The ability to measure multiple forms of cell death simultaneously represents a significant development for such techniques. I have been using antibodies and more specific forms of dyes to identify mitochondrial activity and reactive oxygen in roughly fifty populations, whereas normally it would only be able to measure one at a time. I will be discussing this work at the Flow Cytometry Congress, and it could prove enormously beneficial to drug and immunotherapy development.
Posted 9th January 2019 by Jane Williams
Bas Trietsch is the CTO and co-founder of MIMETAS and co-inventor of the OrganoPlate. As CTO he currently drives the continued product development of the OrganoPlate and its peripheral equipment.
Here, Bas talks about what the future holds for organ-on-a-chip and other breakthroughs technologies in biology.
Posted 10th October 2018 by Jane Williams
This article was originally published by Technology Networks in August 2018 and is published here with permission.
John Baldoni currently heads up a drug discovery unit at GlaxoSmithKline. Since joining GSK in 1989, John has held numerous positions within the company and has led many significant cross-functional strategic initiatives. He has an impressive 37 years’ experience working within the biopharmaceutical industry.
The recently established Accelerating Therapeutics for Opportunities in Medicine consortium, was conceived by John, with a mission “to accelerate the development of more effective therapies for patients”. ATOM stemmed from the Cancer Moonshot, an initiative that aims to improve the availability of cancer therapies, enhance detection of cancer early on, and improve our ability to prevent cancer.
Posted 28th September 2018 by Jane Williams
When we last spoke, Brandon Allgood told us about The Future of AI. This week, we caught up with Brandon and spoke about drug discovery and machine learning algorithms.